Praxbind 2
As listed in the register: Praxbind 2,5 g/50 ml oplossing voor injectie/infusie
2,5 g/50 ml · oplossing voor injectie of infusie
- Prescription only
- Everything that fits nowhere else, such as contrast media
- Active substance
- Idarucizumab
- Made by
- Boehringer Ingelheim International GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Praxbind). It describes the substance, not this exact product.
Idarucizumab is a specific reversal agent for dabigatran.
It is a humanized monoclonal antibody fragment (Fab) that binds to dabigatran and its acylglucuronide metabolites with higher affinity than the binding affinity of dabigatran to thrombin, neutralizing their anticoagulant effect.
A dose-dependent increase in the fraction of unchanged idarucizumab excreted in urine was observed.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2024-01-23
Safety of the active substance
From the US prescribing label for the same active substance (Praxbind). It describes the substance, not this exact product.
The most frequently reported adverse reactions in ≥5% of patients treated with idarucizumab were constipation and nausea.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
CanadaNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Boehringer Ingelheim International GmbH |
|---|---|
| Active substance | Idarucizumab |
| Used in | Everything that fits nowhere else, such as contrast media |
| Strength | 2,5 g/50 ml |
| Form | oplossing voor injectie of infusie |
| Classification | V03AB37 · Everything that fits nowhere else, such as contrast media |
| Route | intraveneus gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| Name in the register | Praxbind 2,5 g/50 ml oplossing voor injectie/infusie |
| RVG | EU/1/15/1056 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).